Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on Praliciguat PK in Healthy Volunteers
NCT03499106Phase 1Completed
- Sponsor
- Cyclerion Therapeutics
- Start
- Apr 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of praliciguat in heart failure with preserved ejection fraction (HFpEF) and diabetic nephropathy (DN), sponsored by Cyclerion Therapeutics. Primary endpoints: Area Under the Plasma Concentration Time Curve From Time Zero Extrapolated to Infinity and Maximum Observed Plasma Concentration. Started Apr 2018; status: completed.
02
Drugs
praliciguat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT03499106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03499106.